Scientists have identified a little-known protein called Miro1 as a potential hidden driver of insulin resistance in type 2 diabetes, according to preclinical research that could open a new therapeutic pathway for the disease. The findings suggest that a buildup of Miro1 impairs the ability of muscle tissue to respond to insulin, a hallmark of the condition. In laboratory experiments, removing the protein restored the muscles' sensitivity to insulin, indicating that targeting Miro1 may help reverse a key mechanism underlying metabolic dysfunction.
The research also revealed that exercise lowers Miro1 levels in people with diabetes, offering a possible explanation for the well-documented benefits of physical activity in managing the disease. While the results are preliminary and derived from preclinical models, they point to a promising avenue for future treatments and reinforce the role of lifestyle interventions. Further clinical studies will be needed to determine whether Miro1 can be safely and effectively targeted in patients, and to clarify how the protein interacts with other factors involved in type 2 diabetes.
Independent reporting synthesized from primary wires and global correspondents.